Cancer medicine · 2026
Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schulze Finn J, Shumilov Evgenii, Behringer Akhil, Kerkhoff Andrea, Eckhardt Matthias, Bätker Simone, Maulhardt Markus, Lenz Georg, Pohlmann Alexander
Аннотация
BACKGROUND: Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized.
METHODS: We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing organ involvement, clinical features, genetic risk factors, and response to therapy.
RESULTS: Different organs were affected, most frequently the kidneys (7/19). Median age at initial CLL diagnosis was 54 years, median time from CLL diagnosis to extranodal manifestation was 3 years. Genetic risk factors were comparable to typical CLL cohorts. Per treatment episode, exploratory overall response rate (ORR) for Bruton tyrosine kinase inhibitors (BTKi) was 88.9% (8/9); median progression-free survival (PFS) from treatment initiation was 29 months. For venetoclax-based regimens, ORR was 83.3% (5/6) and median PFS 52 months.
CONCLUSIONS: These data suggest meaningful activity of BTK and BCL-2 inhibitors in CLL/SLL with extranodal organ involvement.
METHODS: We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing organ involvement, clinical features, genetic risk factors, and response to therapy.
RESULTS: Different organs were affected, most frequently the kidneys (7/19). Median age at initial CLL diagnosis was 54 years, median time from CLL diagnosis to extranodal manifestation was 3 years. Genetic risk factors were comparable to typical CLL cohorts. Per treatment episode, exploratory overall response rate (ORR) for Bruton tyrosine kinase inhibitors (BTKi) was 88.9% (8/9); median progression-free survival (PFS) from treatment initiation was 29 months. For venetoclax-based regimens, ORR was 83.3% (5/6) and median PFS 52 months.
CONCLUSIONS: These data suggest meaningful activity of BTK and BCL-2 inhibitors in CLL/SLL with extranodal organ involvement.